Drug lookup
Drug reference

Mexiletine

Antiarrhythmic · Antiarrhythmic, Skeletal Muscle Relaxant

Also known as Mexiletine hydrochloride

AntiarrhythmicAntiarrhythmic, Skeletal Muscle RelaxantATC C01BB02
CDSCO approvedSchedule HATC C01BB02
EXCRETION
not curated
INTERACTIONS
11 major
SEVERE in our sources
PREGNANCY
not curated
Top interactionssee all 12
  • AminophyllineSevereDatabaseDDInter
  • ArbutamineSevereDatabaseDDInter
  • BupropionSevereDatabaseDDInter
  • DofetilideSevereDatabaseDDInter

Mechanism

Mexiletine is a sodium channel blocker which reduces the delay of muscle relaxation thereby decreasing muscle stiffness. It is also classified as a Class IB antiarrhythmic, acting to control ventricular arrhythmias.

Indications

Life-threatening ventricular arrhythmiasMyotonia in non-dystrophic myotonic disordersChronic treatment to prevent ventricular tachycardiaChronic treatment to prevent ventricular fibrillationCorrecting aberrant late inward Na+ current in type 3 congenital long QT syndromePost-infarction sinister ventricular arrhythmias (parenteral, as alternative to lidocaine)Chronic suppression of ventricular extrasystoles (VES) (oral, questionable merit)Chronic suppression of ventricular tachycardia (VT) (oral, questionable merit)

Dosing

Adult
For myotonia in non-dystrophic myotonic disorders: 167 mg once daily by mouth for at least 1 week, then increased if necessary to 333 mg daily in divided doses for at least 1 week, then increased if necessary to 500 mg daily in divided doses; maintenance 167 500 mg daily.
Max dose
500 mg per day

Pharmacokinetics

Half-life
9–15 h
Bioavailability
>80%
Protein binding
excreted in urine
Metabolism
Hepatic metabolism (inducible by phenytoin)

Contraindications

  • Abnormal Q-waves
  • Atrial tachyarrhythmia, fibrillation or flutter
  • Complete heart block or any heart block susceptible to evolve to complete heart block
  • Heart failure (with ejection fraction less than 50%)
  • History of myocardial infarction
  • Sinus node dysfunction
  • Symptomatic coronary artery disease
  • Ventricular tachyarrhythmia
  • Tremor

Side effects

Common
Abdominal painArrhythmiasAstheniaChest discomfortDrowsinessHeadacheHypotensionInsomniaMalaiseNauseaPain in extremityParaesthesiaSkin reactionsVasodilationVertigoVision disordersTremorVomitingDizzinessConfusionBlurred visionAtaxia
Serious
  • Seizure
  • Speech disorder
  • Hepatic disorders
  • Severe cutaneous adverse reactions (SCARs)
  • Atrioventricular block
  • Circulatory collapse
  • Hallucination
  • Bradycardia (with i.v. injection)
  • Hypotension (with i.v. injection)
  • Accentuation of A-V block (with i.v. injection)

Drug interactions

Aminophylline
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Arbutamine
Severe
Database

Clinical effect not specified

Source: DDInter

Bupropion
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Dofetilide
Severe
Database

Clinical effect not specified

Source: DDInter

Droperidol
Severe
Database

Clinical effect not specified

Source: DDInter

Iohexol
Severe
Database

Clinical effect not specified

Source: DDInter

Iopamidol
Severe
Database

Clinical effect not specified

Source: DDInter

Rasagiline
Severe
Database

Clinical effect not specified

Source: DDInter

Theophylline
Severe
Database

Clinical effect not specified

Source: DDInter

Tizanidine
Severe
Database

Clinical effect not specified

Source: DDInter

Tramadol
Severe
Database

Clinical effect not specified

Source: DDInter

Haloperidol
Moderate
Textbook

Increased haloperidol exposure (average 62.5%).

Monitor for increased side effects; dose reduction may be needed.

Source: G&G 14e · p369

Related guidelines

Other Antiarrhythmic drugs

Ask House about Mexiletine

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team